secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0001093557-24-000143
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q2 rev $1.004B (+15%); GAAP EPS $0.35; lowers FY rev guidance to $4.00-4.05B
--------------------------------------------------------------------------------

- Revenue $1.004B (+15% YoY); US +19%, intl +7% reported; organic growth 16%.
- GAAP EPS $0.35, Non-GAAP EPS $0.43; GAAP operating income $158.0M (15.7% margin).
- FY2024 revenue guidance lowered to ~$4.00-4.05B (11-13% organic); Q3 rev guidance $975M-$1.00B.
- Announces $750M share repurchase program authorized through June 30, 2025.
- CEO Kevin Sayer acknowledges execution shortfall but cites long-term growth opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000143/0001093557-24-000143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000143/dxcm-20240725.htm
  HTML page:      https://secwatch.observer/filing/0001093557-24-000143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer